The use of randomized control trials to assess the usefulness of therapeutic drugs over the last half century has brought significant benefits to patient care.
The full potential benefits, however, have been only partially fulfilled because available data are frequently poorly used.
Meta-analysis has emerged as an important tool for combining clinical evidence.
Several examples are presented that compared the results of cumulative meta-analysis of randomized control trials with clinical expert recommendations.
These comparisons demonstrated that clinical expert recommendations are often not synchronized with accumulating evidence, and this lack of recognition often resulted in delays in the acceptance of effective drugs and the slow abandonment of possibly harmful therapeutic practices.
The problems of inappropriate therapeutic drug use will only intensify as new drugs are introduced and new uses for established drugs are proposed.
The rational use of therapeutic drugs can be achieved only through the routine use of meta-analysis on high-quality clinical data.
Some suggestions are made to improve the quality of the original research and the ways of assembling meta-analyses and disseminating their results.
Mots-clés Pascal : Médicament, Utilisation, Rationalisation, Essai clinique, Métaanalyse, Randomisation, Homme
Mots-clés Pascal anglais : Drug, Use, Rationalization, Clinical trial, Metaanalysis, Randomization, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0590233
Code Inist : 002B30A08. Création : 01/03/1996.